|
40 Companies |
|
48 Products |
|
48 Products |
|
0 Mechanisms of Action |
|
20 Trials |
|
419 News |
|
| «12345678» |
- hydroxyurea / Generic mfg.
Trial termination: Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE) (clinicaltrials.gov) - Jan 26, 2014
P3, N=38, Terminated, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Terminated; inability to reach a satisfactory endpoint with respect to adequate recruitment
- hydroxyurea / Generic mfg.
Enrollment change: Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE) (clinicaltrials.gov) - Jan 26, 2014
P3, N=38, Terminated, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Terminated; inability to reach a satisfactory endpoint with respect to adequate recruitment N=115 --> 38
- | hydroxyurea / Generic mfg.
New P2 trial, Adherence: Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT (clinicaltrials.gov) - Jan 6, 2014
P2, N=60, Recruiting, Sponsor: Columbia University
- warfarin / Generic mfg.
Trial termination: Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease (clinicaltrials.gov) - Jan 5, 2014
P2, N=3, Terminated, Sponsor: University of North Carolina, Chapel Hill
N=115 --> 38 Recruiting --> Terminated; Difficulty in accruing subjects
- warfarin / Generic mfg.
Enrollment change: Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease (clinicaltrials.gov) - Jan 5, 2014
P2, N=3, Terminated, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Terminated; Difficulty in accruing subjects N=20 --> 3
- Clinical: Drépano: Systematic Psychological and Medical Care for Children With SCD (clinicaltrials.gov) - Dec 26, 2013
P=N/A, N=160, Recruiting, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
- propranolol ER / Generic mfg.
New P1 trial: Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease (clinicaltrials.gov) - Dec 12, 2013
P1, N=20, Recruiting, Sponsor: University of Miami
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders (clinicaltrials.gov) - Dec 9, 2013
P2, N=50, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=20 --> 3 N=25 --> 50
- Trial termination: Nitric Oxide and Sickle Cell Pain (clinicaltrials.gov) - Dec 5, 2013
P=N/A, N=12, Terminated, Sponsor: National Institute of Nursing Research (NINR)
N=25 --> 50 Recruiting --> Terminated
- Enrollment change: Nitric Oxide and Sickle Cell Pain (clinicaltrials.gov) - Dec 5, 2013
P=N/A, N=12, Terminated, Sponsor: National Institute of Nursing Research (NINR)
Recruiting --> Terminated N=90 --> 12
- | HQK 1001 / Viracta Therap
Trial termination: Effects of HQK-1001 in Patients With Sickle Cell Disease (clinicaltrials.gov) - Nov 25, 2013
P2, N=77, Terminated, Sponsor: HemaQuest Pharmaceuticals Inc.
N=90 --> 12 Active, not recruiting --> Terminated
- | Trial initiation date: SOMMEDREP: Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children (clinicaltrials.gov) - Nov 11, 2013
P2/3, N=280, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Terminated Initiation date: Sep 2013 --> Jan 2014
- || hydroxyurea / Generic mfg.
New P3 trial: NOHARM: Novel Use Of Hydroxyurea in an African Region With Malaria (clinicaltrials.gov) - Nov 3, 2013
P3, N=200, Not yet recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
- Enrollment open: Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - Oct 31, 2013
P=N/A, N=250, Recruiting, Sponsor: St. Jude Children's Research Hospital
Initiation date: Sep 2013 --> Jan 2014 Not yet recruiting --> Recruiting
- Trial withdrawal: Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis (clinicaltrials.gov) - Oct 24, 2013
P2, N=0, Withdrawn, Sponsor: Sangart
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Enrollment change: Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis (clinicaltrials.gov) - Oct 24, 2013
P2, N=0, Withdrawn, Sponsor: Sangart
Not yet recruiting --> Withdrawn N=200 --> 0
- Enrollment change: Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting (clinicaltrials.gov) - Oct 16, 2013
P=N/A, N=88, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
N=200 --> 0 N=300 --> 88
- Enrollment closed: Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting (clinicaltrials.gov) - Oct 16, 2013
P=N/A, N=88, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
N=300 --> 88 Recruiting --> Active, not recruiting
- Enrollment closed: DREPAGREFFE: Allogeneic Genoidentical Stem Cell Transplantation in Children With Sickle-cell Anemia and Cerebral Vasculopathy (clinicaltrials.gov) - Oct 10, 2013
P=N/A, N=63, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | montelukast / Generic mfg.
New P2 trial, P2 data: Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (clinicaltrials.gov) - Oct 8, 2013
P2, N=63, Recruiting, Sponsor: Vanderbilt University
- Enrollment open: Pain Management in Children and Young Adults With Sickle Cell Disease (clinicaltrials.gov) - Oct 7, 2013
P2, N=190, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | New P2 trial: Pain Management in Children and Young Adults With Sickle Cell Disease (clinicaltrials.gov) - Oct 4, 2013
P2, N=190, Recruiting, Sponsor: St. Jude Children's Research Hospital
- sildenafil / Generic mfg.
Trial termination: Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia (clinicaltrials.gov) - Sep 19, 2013
P2, N=13, Terminated, Sponsor: Johns Hopkins University
Not yet recruiting --> Recruiting Recruiting --> Terminated; funding was terminated
- sildenafil / Generic mfg.
Enrollment change: Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia (clinicaltrials.gov) - Sep 19, 2013
P2, N=13, Terminated, Sponsor: Johns Hopkins University
Recruiting --> Terminated; funding was terminated N=20 --> 13
- Trial termination: SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease (clinicaltrials.gov) - Sep 15, 2013
P0, N=3, Terminated, Sponsor: Emory University
N=20 --> 13 Recruiting --> Terminated; lack of enrollment
- Enrollment change: SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease (clinicaltrials.gov) - Sep 15, 2013
P0, N=3, Terminated, Sponsor: Emory University
Recruiting --> Terminated; lack of enrollment N=12 --> 3
- ||||| Clotinab (abciximab) / Isu Abxis
New P2 trial: Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis (clinicaltrials.gov) - Aug 28, 2013
P2, N=100, Recruiting, Sponsor: St. Louis University
- Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Enrollment open: Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients (clinicaltrials.gov) - Aug 25, 2013
P1, N=24, Recruiting, Sponsor: Prolong Pharmaceuticals
N=12 --> 3 Not yet recruiting --> Recruiting
- Enrollment closed: Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease (clinicaltrials.gov) - Aug 21, 2013
P=N/A, N=279, Active, not recruiting, Sponsor: University of Illinois at Chicago
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- simvastatin / Generic mfg.
Enrollment change: Simvastatin (Zocor) Therapy in Sickle Cell Disease (clinicaltrials.gov) - Aug 19, 2013
P1/2, N=42, Completed, Sponsor: Children's Hospital & Research Center Oakland
Recruiting --> Active, not recruiting N=28 --> 42
- New P2 trial: Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis (clinicaltrials.gov) - Aug 15, 2013
P2, N=0, Withdrawn, Sponsor: Sangart
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial suspension: A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease (clinicaltrials.gov) - Aug 11, 2013
P2, N=25, Suspended, Sponsor: Nationwide Children's Hospital
N=28 --> 42 Recruiting --> Suspended
- | Fragmin (dalteparin sodium) / Pfizer, Eisai
Enrollment change: Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo (clinicaltrials.gov) - Aug 8, 2013
P2, N=34, Active, not recruiting, Sponsor: Duke University
Recruiting --> Suspended N=100 --> 34
- | Fragmin (dalteparin sodium) / Pfizer, Eisai
Enrollment closed: Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo (clinicaltrials.gov) - Aug 8, 2013
P2, N=34, Active, not recruiting, Sponsor: Duke University
N=100 --> 34 Recruiting --> Active, not recruiting
- hydroxyurea / Generic mfg.
Enrollment change: HYDREP: Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated (clinicaltrials.gov) - Aug 5, 2013
P4, N=50, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting N=34 --> 50
- hydroxyurea / Generic mfg.
Trial completion: HYDREP: Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated (clinicaltrials.gov) - Aug 5, 2013
P4, N=50, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=34 --> 50 Recruiting --> Completed
- ||||| Enrollment change: Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study) (clinicaltrials.gov) - Jul 31, 2013
P2/3, N=100, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Completed N=260 --> 100
- ||||||| Trial completion: Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study) (clinicaltrials.gov) - Jul 31, 2013
P2/3, N=100, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=260 --> 100 Recruiting --> Completed
- hydroxyurea / Generic mfg.
Enrollment closed: ELYSIS: Long Term Effects of Erythrocyte Lysis (clinicaltrials.gov) - Jul 30, 2013
P=N/A, N=390, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change: Psychometric Evaluation of the IPPAQ in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=159, Completed, Sponsor: Connecticut Children's Medical Center
Recruiting --> Active, not recruiting N=200 --> 159
- Enrollment change: Assessing Function in Pediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=25, Completed, Sponsor: Connecticut Children's Medical Center
N=200 --> 159 N=53 --> 25
- Trial completion: Psychometric Evaluation of the IPPAQ in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=159, Completed, Sponsor: Connecticut Children's Medical Center
N=53 --> 25 Recruiting --> Completed
- Trial completion: Validation of the Sickle Cell Disease Pain Burden Interview (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=131, Completed, Sponsor: Connecticut Children's Medical Center
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Assessing Function in Pediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=25, Completed, Sponsor: Connecticut Children's Medical Center
Recruiting --> Completed Active, not recruiting --> Completed
- Trial withdrawal, IO biomarker: A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension (clinicaltrials.gov) - Jul 25, 2013
P2, N=0, Withdrawn, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Terminated --> Withdrawn
- Enrollment open: Treatment of Sickle Cell Anemia With Stem Cell Transplant (clinicaltrials.gov) - Jul 23, 2013
P=N/A, N=12, Recruiting, Sponsor: Thomas Jefferson University
Terminated --> Withdrawn Withheld --> Recruiting
- ||||| vepoloxamer (MST-188) / Savara
Trial initiation date: Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) (clinicaltrials.gov) - Jul 21, 2013
P3, N=388, Recruiting, Sponsor: Mast Therapeutics, Inc.
Withheld --> Recruiting Initiation date: Jan 2013 --> May 2013
- || Enrollment change: Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients (clinicaltrials.gov) - Jul 21, 2013
P=N/A, N=73, Completed, Sponsor: Terumo BCT
Initiation date: Jan 2013 --> May 2013 N=60 --> 73
- ||| Trial completion: Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients (clinicaltrials.gov) - Jul 21, 2013
P=N/A, N=73, Completed, Sponsor: Terumo BCT
N=60 --> 73 Recruiting --> Completed
- Enrollment closed: Clinical Diagnosis of Teenagers Admitted to Pediatric Departments (clinicaltrials.gov) - Jul 15, 2013
P=N/A, N=5000, Active, not recruiting, Sponsor: HaEmek Medical Center, Israel
Recruiting --> Completed Recruiting --> Active, not recruiting